Latest Commercialisation News

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.

Rhythm Biosciences has secured a multi-year commercial manufacturing agreement with US-based Quansys Biosciences to produce ColoSTAT® reagent kits, paving the way for broader market rollout of its colorectal cancer diagnostic test.

Biome Australia has secured ethics approval to commence a pivotal human clinical trial of its proprietary probiotic strain BMB18, aiming to validate its benefits on digestive, sleep, and mood health.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

Cyclopharm has reported a record $32.3 million in operating revenue for FY2025, led by explosive growth in its U.S. Technegas market following FDA approval. The company reaffirms its ambitious target of 250–300 U.S. installations by mid-2026 amid strong clinical momentum.

Neurotech International has secured ethics approval to launch its Beyond Harmony Phase 3 clinical trial of NTI164 for autism spectrum disorder, marking a key step toward regulatory submissions in Australia and the US.

FortifAI Limited has completed its acquisition of FastAI Pty Ltd, gaining control of the innovative Nol8 technology and appointing seasoned executive Yosef Keret as director and Celerriem CEO.

Genetic Signatures has appointed Maria Halasz as its new CEO, bringing over two decades of leadership in life sciences and capital markets to steer the company’s global expansion.

Orthocell Ltd reports steady progress in commercialising its nerve repair product Remplir in the US, with sales growth, expanded distributor networks, and manufacturing upgrades underpinning its path to profitability.

Memphasys Limited secures significant repeat orders from Hamad Medical Corporation, marking a pivotal expansion of its Felix™ system across the MENA region.

Provaris Energy and Yinson Production have teamed up with Himile Heavy Industries to explore manufacturing large-scale LCO₂ tanks in China, a key step for offshore carbon capture infrastructure.

Critical Resources Limited has secured a strategic position within the US Centre for Solid-State Electric Power Storage, accelerating its evaluation and development of safer, higher-performance solid-state lithium-ion batteries.